CLRB

$1.31+7.38%visit website

Cellectar Biosciences, Inc.

Market Cap

$12M

Live price × SEC shares (Aug 11, 2026)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

0.64

60mo monthly vs SPY

P/E (TTM)

N/M

TTM to Jun 2026 · negative earnings

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

0.4

Mkt cap / shareholders' equity

Flagged input, hover for details

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q3 FY2025 Sep 30, 2025	Q4 FY2025 Dec 31, 2025	Q1 FY2026 Mar 31, 2026	Q2 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	2,523	3,159	3,007	4,557	13,246
Operating income	(4,851)	(5,691)	(5,794)	(7,196)	(23,531)
Net income	(4,444)	(5,295)	(5,654)	(6,931)	(22,324)
EPS (basic) ($)	(1.41)		(1.33)	(0.57)	—
EPS (diluted) ($)	(1.41)		(1.33)	(0.57)	—
Weighted avg. shares (basic)	3,162		4,240	12,232
Weighted avg. shares (diluted)	3,162		4,240	12,232

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-Q filed Aug 13, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 61 more quarters, back to Jun 2010, with Tormere Pro.

Corporate Events (8-K)

7 filings in 12 months · 0 with priority itemsFull history →

Filed	Items	Filing
Aug 13, 2026 accepted 7:25 AM ET	2.02Earnings release	Document SEC ↗
Jul 10, 2026 accepted 5:13 PM ET	5.02Officer / director change5.07Shareholder vote	Document SEC ↗
May 18, 2026 accepted 4:15 PM ET	5.02Officer / director change	Document SEC ↗
May 14, 2026 accepted 7:20 AM ET	2.02Earnings release	Document SEC ↗
May 8, 2026 accepted 6:04 AM ET	1.01Material agreement3.02Unregistered equity sale8.01Other events	Document SEC ↗
Mar 4, 2026 accepted 7:23 AM ET	2.02Earnings release	Document SEC ↗
Nov 13, 2025 accepted 7:30 AM ET	2.02Earnings release	Document SEC ↗
Oct 10, 2025 accepted 4:30 PM ET	1.01Material agreement2.02Earnings release3.02Unregistered equity sale3.03Holder rights modified8.01Other events	Document SEC ↗
Oct 6, 2025 accepted 7:15 AM ET	7.01Reg FD disclosure8.01Other events	Document SEC ↗
Aug 14, 2025 accepted 7:30 AM ET	2.02Earnings release	Document SEC ↗

Signals

purchases / sales, 90d

Short Volume

55%

W/W +7.3pp

Market & Alt Data

News

Factor Profile

Pro

Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro

Sort by

Type

Trade Date	Filed	Owner	Role	Type	Shares	Price	Value	Owned After
2026-05-07	2026-05-11	Longcor Jarrod	Chief Operating Officer	Purchase	8,680	$2.88	$25K	20.5K	View
2026-05-07	2026-05-11	CARUSO JAMES V	Director & Chief Executive Officer	Purchase	8,680	$2.88	$25K	20.3K	View
2025-12-12	2025-12-16	NEIS JOHN	Director	Sale	198	$3.70	$731.99	10	View
2025-07-02	2025-07-03	CARUSO JAMES V	Director & Chief Executive Officer	Purchase	10.0K	$4.99	$50K	11.6K	View
2025-07-02	2025-07-03	Longcor Jarrod	Chief Operating Officer	Purchase	10.0K	$4.99	$50K	12.8K	View